Tocagen — Forte Biosciences — Investor Presentation (May 2024)
32 slides from Tocagen's investor presentation, May 13, 2024
Slide 1: Forte Biosciences FB-102 Overview Corporate Deck
Exhibit 99.2 FORTE BIOSCIENCES FB-102 OVERVIEW CORPORATE DECK MAY 13, 2024 1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS ¡ Certain statements contained in this presentation regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securitie
Slide 3: Forte Biosciences Overview
FORTE BIOSCIENCES OVERVIEW • Forte Biosciences, Inc is a clinical stage public biotechnology company (Nasdaq: FBRX) • Strong Board of Directors comprised of leaders in industry including: • Scott Brun, MD – Former head of Abbvie product development • David Gryska – Former CFO of Incyte and Celgene •
Slide 4: Experienced Management
EXPERIENCED MANAGEMENT Forte’s management has extensive experience in manufacturing, quality, regulatory and clinical development Paul Wagner, Ph.D., CFA – CEO Tony Riley – Chief Financial Officer Chris Roenfeldt, PMP – Chief Operating Officer Steven Ruhl – Chief Technical Officer Barbara Finck, M.D
Slide 5: FB-102 Program Overview
FB-102 PROGRAM OVERVIEW 5
Slide 6: Clinical Stage FB-102 Overview
CLINICAL STAGE FB-102 OVERVIEW • CD122 is a subunit of the intermediate affinity IL-2/IL-15 receptor expressed on NK cells, T cells and is a subunit of the high affinity IL-2 receptor expressed on Tregs, • FB-102 (Forte’s anti-CD122 antibody) is designed to mediate both the IL-2 and the IL-15 induce
Slide 7: Highlights of Existing Preclinical Anti-CD122 Proof of Concept Data
HIGHLIGHTS OF EXISTING PRECLINICAL ANTI-CD122 PROOF OF CONCEPT DATA 7
Slide 8: Partial List of Positive POC Animal Data for Anti-CD122
PARTIAL LIST OF POSITIVE POC ANIMAL DATA FOR ANTI-CD122 HIGHLIGHTS FB-102 “PIPELINE-IN-A-PRODUCT” POTENTIAL Disease Species Outcome Reference GVHD Mouse Prolonged survival JN Bio patent, 2015 Vitiligo Mouse Enhanced repigmentation Sci Transl Med, 2018 Alopecia areata Mouse Prevented fur loss Nature
Slide 9: CD-122 Blockade Produces Significant Repigmentation in Mouse Vitiligo Model
CD-122 BLOCKADE PRODUCES SIGNIFICANT REPIGMENTATION IN A MOUSE VITILIGO MODEL Richmond et al. Sci Transl Med. 2018 July 18; 10(450) Following 8 weeks of anti-CD122 treatment (weeks 12-20), the vitiligo mice demonstrated a statistically significant change in tail pigmentation (p=0.0001) 9
Slide 10: Anti-CD122 in Mouse Model of Vitiligo: Durable Response with Infrequent Dosing
ANTI-CD122 IN A MOUSE MODEL OF VITILIGO: POTENTIAL OF DURABLE RESPONSE WITH INFREQUENT DOSING REGIMEN Note: anti-mouse CD122 (surrogate molecule) was used in these studies. 10
Slide 11: Anti-CD122 as Prophylaxis Against Fur Loss in Mouse Alopecia Areata Model
ANTI-CD122 AS AN EFFECTIVE PROPHYLAXIS AGAINST FUR LOSS IN A MOUSE MODEL OF ALOPECIA AREATA Anti-CD122 C3H/HeJ mice were treated systemically from the time of grafting with anti-CD122. Xing et al. Nature Medicine Vol 20, No. 9, p 1043 11 Note: anti-mouse CD122 (surrogate molecule) was used in these
Slide 12: FB-102 Development Strategy
FB-102 DEVELOPMENT STRATEGY 12
Slide 13: Large Unmet Need in Vitiligo and Alopecia Areata
LARGE UNMET NEED IN VITILIGO AND ALOPECIA AREATA (COMBINED $6 BILLION MARKET BY 2026) Vitiligo Vitiligo is an autoimmune disease of the skin mediated primarily by NK and CD8+ T cells that kill melanocytes and create white spots. In the US there are approximately 2 m people with vitiligo. The global
Slide 14: Graft vs Host Disease: A Serious Complication of Allogeneic Stem Cell Transplantation
GRAFT VS HOST DISEASE (GVHD): A SERIOUS COMPLICATION OF ALLOGENEIC STEM CELL TRANSPLANTATION Cause: donor immune cells attack host tissues Classification Acute (~5K US prevalence - NIH) - Occurs in up to 50% of recipients. - Onset typically within 3 months of transplant - Usually combination or orga
Slide 15: CD8 and NK Cells in Pathogenesis of Acute GVHD: Potential of Anti-CD122
CD8 AND NK CELLS IN THE PATHOGENESIS OF ACUTE GVHD: POTENTIAL OF ANTI-CD122 ANTAGONISM WITH FB102 Anti-CD122: blocking key cellular mediators of GVHD IFNg IL-2 Inflammation & apoptosis Devetten MP, Biol Blood Marrow Transplant. 2004;10:815. Simonetta F, Front Immunol. 2017;8:465. Khandelwal P, Biol
Slide 16: Background on Graft vs Host Disease
BACKGROUND ON GRAFT VS HOST DISEASE 16
Slide 17: Acute GVHD: Treatment Paradigm and Development Pipeline
ACUTE GVHD: TREATMENT PARADIGM AND DEVELOPMENT PIPELINE https://www.lls.org/booklet/graft-versus-host-disease https://www.jakafi.com/pdf/prescribing-information.pdf 17
Slide 18: Potential Indications and Clinical Success Criteria of Anti-CD122 in Acute GVHD
POTENTIAL INDICATIONS AND CLINICAL SUCCESS CRITERIA OF ANTI-CD122 IN ACUTE GVHD Corticosteroids First-line Goal: improve Day 28 ORR vs. Anti- Second-line CD122 ruxolitinib monotherapy https://www.lls.org/booklet/graft-versus-host-disease https://www.jakafi.com/pdf/prescribing-information.pdf 18
Slide 19: Approval of Ruxolitinib in Acute GVHD Based on Open-Label Single-Arm Study
APPROVAL OF RUXOLITINIB IN ACUTE GVHD WAS BASED ON THE RESULTS FROM AN OPEN-LABEL, SINGLE-ARM STUDY Efficacy is based on Day 28 overall response rate as defined by CIBMTR criteria. https://www.jakafi.com/pdf/prescribing-information.pdf 19
Slide 20: Chronic GVHD: Treatment Paradigm and Development Pipeline
CHRONIC GVHD: TREATMENT PARADIGM AND DEVELOPMENT PIPELINE https://www.lls.org/booklet/graft-versus-host-disease https://www.rxabbvie.com/pdf/imbruvica_pi.pdf https://www.jakafi.com/pdf/prescribing-information.pdf https://products.sanofi.us/rezurock/rezurock.pdf 20
Slide 21: Potential Indications and Clinical Success Criteria of Anti-CD122 in Chronic GVHD
POTENTIAL INDICATIONS AND CLINICAL SUCCESS CRITERIA OF ANTI-CD122 IN CHRONIC GVHD Corticosteroids First-line Second-line Goal: improve Month 6 ORR Anti- (esp. CR) vs. standard of care. CD122 Third-line Anti- Fourth-line https://www.lls.org/booklet/graft-versus-host-disease Goal: achieve Month 6 ORR
Slide 22: Approval of Rezurock in Chronic GVHD Based on Open-Label Single-Arm Study
APPROVAL OF REZUROCK IN CHRONIC GVHD WAS BASED ON THE RESULTS FROM AN OPEN-LABEL, SINGLE-ARM STUDY Efficacy is based on overall response rate after 6 months of treatment as defined by the 2014 NIH response criteria. https://products.sanofi.us/rezurock/rezurock.pdf 22
Slide 23: 23
23
Slide 24: Chronic GVHD Study with Anti-CD122 and Ruxolitinib
CHRONIC GVHD STUDY WITH ANTI-CD122 AND RUXOLITINIB End of Treatment start study 40 50 60 Day 1 10 20 30 Vehicle FB650 (100 mpk IP every other day) Ruxolitinib (60 mpk PO twice daily) N=16-18 per group 24
Slide 25: Chronic GVHD Study Results: GVHD Score
CHRONIC GVHD STUDY RESULTS: GVHD SCORE Treatment start 3 Vehicle Vehicle 2 Anti-CD122 Ruxolitinib Ruxolitinib 1 0 Anti-CD122 30 34 38 42 46 50 54 58 62 66 Days after transplant Mean (SEM), n=16-18 per group Day 60 results: P<0.01 for Vehicle vs Anti-CD122, P<0.05 for Ruxolitinib vs Anti-CD122 25 GVH
Slide 26: Generating Preclinical Efficacy Data in Humanized Mouse Model of Acute GVHD
GENERATING PRECLINICAL EFFICACY DATA IN A HUMANIZED MOUSE MODEL OF ACUTE GVHD Humanized mouse model of graft vs host disease 26
Slide 27: Dose-Ranging Investigation of FB102 in Humanized Mouse Model of Acute GVHD
DOSE-RANGING INVESTIGATION OF FB102 IN A HUMANIZED MOUSE MODEL OF ACUTE GVHD: THERAPEUTIC MODE Irradiation & End of PBMC transplantation treatment 1 2 3 4 5 6 8 10 12 13 14 Day 7 9 11 FB102 Once-daily IP administration Start dosing on Day 5, (75, 125, 175 mpk) once daily Vehicle Once-daily IP admini
Slide 28: FB102 Survival Benefits: Therapeutic Mode
FB102 SURVIVAL BENEFITS: THERAPEUTIC MODE FB-102 Start of daily treatment superior to 1 1 1 1 10 0 0 0 00 0 0 0 0% % % % % FB102(75): 90% aGvHD FB102(175): 90% 8 8 8 8 80 0 0 0 0% % % % % FB102(125): 80% standard of care, 6 6 6 6 60 0 0 0 0% % % % % Ruxolitinib: 60% ruxolitinib, head to head 4 4 4 4
Slide 29: Mono vs Combination Therapies with FB102, Ruxolitinib or Corticosteroids
MONO VS COMBINATION THERAPIES WITH FB102, RUXOLITINIB OR CORTICOSTEROIDS Irradiation & End of study PBMC injection (D18) Day 1 5 8 12 15 18 Ruxolitinib Twice-daily oral (60 mpk) FB102+Ruxolitinib Once-daily IP + twice-daily oral (75 mpk+60 mpk) Placebo Once-daily IP + twice-daily oral (Combination o
Slide 30: FB102 Survival Benefits: Combination with Ruxolitinib Superior to Ruxolitinib Alone
FB102 SURVIVAL BENEFITS: COMBINATION OF FB-102 WITH RUXOLITINIB SIGNIFICANTLY SUPERIOR TO RUXOLITINIB ALONE Start of daily treatment FB-102/rux 100% 1 10 00 0% % combo FB102+Rux: 90% significantly 8 8 80 0 0% % % superior to standard of care 6 6 60 0 0% % % single agent, 4 4 40 0 0% % % ruxolitinib,
Slide 31: Translation of Humanized Acute GVHD Mouse Findings into Patient Response
TRANSLATION OF HUMANIZED ACUTE GVHD MOUSE FINDINGS INTO PATIENT RESPONSE: PROMISING FB102 RESULTS Magnitude of FB102 preclinical efficacy correlates with positive clinical response. Preclinical Data Indication/ Clinical Data Company Candidate Mechanism (survival in humanized Phase (Day 28 ORR) GVHD
Slide 32: Clinical Stage FB-102 Overview
CLINICAL STAGE FB-102 OVERVIEW • CD122 is a subunit of the intermediate affinity IL-2/IL-15 receptor expressed on NK cells, T cells and is a subunit of the high affinity IL-2 receptor expressed on Tregs. • FB-102 (Forte’s anti-CD122 antibody) is designed to mediate both the IL-2 and the IL-15 induce